BR112021024810A2 - Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas - Google Patents

Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas

Info

Publication number
BR112021024810A2
BR112021024810A2 BR112021024810A BR112021024810A BR112021024810A2 BR 112021024810 A2 BR112021024810 A2 BR 112021024810A2 BR 112021024810 A BR112021024810 A BR 112021024810A BR 112021024810 A BR112021024810 A BR 112021024810A BR 112021024810 A2 BR112021024810 A2 BR 112021024810A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
compound
treatment
cancer
pharmaceutical composition
Prior art date
Application number
BR112021024810A
Other languages
English (en)
Inventor
Annick Goergler
Antonio Ricci
Bernd Kuhn
Ulrike OBST-SANDER Christa
Cosimo Dolente
Daniel Rueher
Stephen HEWINGS David
Georg Jaeschke
David Norcross Roger
Sandra Steiner
Alice Nagel Yvonne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021024810A2 publication Critical patent/BR112021024810A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas a. invenção fornece novos compostos como aqui descritos, composições incluindo os compostos e métodos de uso dos compostos.
BR112021024810A 2019-06-21 2020-06-19 Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas BR112021024810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21
PCT/EP2020/067055 WO2020254546A1 (en) 2019-06-21 2020-06-19 New egfr inhibitors

Publications (1)

Publication Number Publication Date
BR112021024810A2 true BR112021024810A2 (pt) 2022-01-25

Family

ID=67001684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024810A BR112021024810A2 (pt) 2019-06-21 2020-06-19 Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas

Country Status (19)

Country Link
US (2) US20220315591A1 (pt)
EP (2) EP3986567B1 (pt)
JP (2) JP2022537771A (pt)
KR (1) KR20220024096A (pt)
CN (2) CN113993590A (pt)
AR (2) AR121167A1 (pt)
AU (1) AU2020296933A1 (pt)
BR (1) BR112021024810A2 (pt)
CA (1) CA3139171A1 (pt)
CL (1) CL2021003373A1 (pt)
CO (1) CO2021016967A2 (pt)
CR (1) CR20210614A (pt)
IL (1) IL287806A (pt)
MA (1) MA56507A (pt)
MX (1) MX2021015889A (pt)
PE (1) PE20220807A1 (pt)
TW (2) TW202115070A (pt)
WO (2) WO2020254547A1 (pt)
ZA (1) ZA202108775B (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307365B1 (en) 2008-06-25 2013-03-27 Merck Sharp & Dohme Corp. Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2016183534A1 (en) 2015-05-14 2016-11-17 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
US10385019B2 (en) * 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
CR20200625A (es) * 2018-06-29 2021-02-05 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
EP3986566B1 (en) 2023-08-30
MX2021015889A (es) 2022-02-03
WO2020254546A1 (en) 2020-12-24
AR121167A1 (es) 2022-04-27
IL287806A (en) 2022-01-01
CN113993591A (zh) 2022-01-28
TW202115073A (zh) 2021-04-16
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
AU2020296933A1 (en) 2021-12-02
WO2020254547A1 (en) 2020-12-24
EP3986566C0 (en) 2023-08-30
EP3986566A1 (en) 2022-04-27
ZA202108775B (en) 2022-09-28
TW202115070A (zh) 2021-04-16
AR119207A1 (es) 2021-12-01
EP3986567C0 (en) 2023-08-30
CO2021016967A2 (es) 2022-01-17
EP3986567A1 (en) 2022-04-27
US20220315591A1 (en) 2022-10-06
PE20220807A1 (es) 2022-05-20
JP2022537772A (ja) 2022-08-29
CA3139171A1 (en) 2020-12-24
JP2022537771A (ja) 2022-08-29
CN113993590A (zh) 2022-01-28
CL2021003373A1 (es) 2022-10-07
US20220112199A1 (en) 2022-04-14
MA56507A (fr) 2022-04-27
EP3986567B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
CL2020003339A1 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112021017772A2 (pt) Bloqueadores de canais de íons carregados e métodos para uso
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CR20180521A (es) Inhibidores del potenciador del homólogo zeste 2
BR112022009086A2 (pt) Inibidores alostéricos de egfr e métodos de uso dos mesmos
BR112022003357A2 (pt) Compostos heterocíclicos
AU2020231934A8 (en) Compounds useful in HIV therapy
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
BR112021017809A2 (pt) Bloqueadores de canais iônicos substituídos por éster e métodos para uso
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método